Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma
暂无分享,去创建一个
R. Lhommel | N. Mounier | L. Michaux | M. Vekemans | E. W. Van Den Neste | M. André | T. Vander Borght | A. Sonet | A. Bosly | Salima Bouazza | N. Nols | S. Costantini | E. Van Den Neste
[1] F. De Keyzer,et al. Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot study , 2013, Cancer imaging : the official publication of the International Cancer Imaging Society.
[2] C. Moskowitz. Interim PET-CT in the management of diffuse large B-cell lymphoma. , 2012, Hematology. American Society of Hematology. Education Program.
[3] B. Coiffier,et al. Baseline Metabolic Tumor Volume Is Predictive of Patient Outcome in Diffuse Large B Cell Lymphoma , 2012 .
[4] S. Ferrero,et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. , 2012, Blood.
[5] C. Copie-Bergman,et al. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] B. Coiffier,et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. , 2011, Blood.
[7] Sang-We Kim,et al. Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP , 2011, Annals of Hematology.
[8] J. Min,et al. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. , 2011, European journal of cancer.
[9] Andrew Homb,et al. 18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation , 2011, The Journal of Nuclear Medicine.
[10] C. Haioun,et al. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010 , 2010, Leukemia & lymphoma.
[11] M. Juweid,et al. Improvement of Early 18F-FDG PET Interpretation in Diffuse Large B-Cell Lymphoma: Importance of the Reference Background , 2010, The Journal of Nuclear Medicine.
[12] M. Juweid,et al. Can the interim fluorodeoxyglucose-positron emission tomography standardized uptake value be used to determine the need for residual mass biopsy after dose-dense immunochemotherapy for advanced diffuse large B-cell lymphoma? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] B. Coiffier,et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.
[14] K. Jöckel,et al. Pitfalls of interim positron emission tomography scanning in diffuse large B-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Trotman,et al. Role of early PET in the management of diffuse large B-cell lymphoma , 2010, Current opinion in oncology.
[16] W. Wilson,et al. The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma , 2010, Leukemia & lymphoma.
[17] M. Meignan. Interim PET in lymphoma: a step towards standardization , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[18] A. Zelenetz,et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Zelenetz,et al. An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[20] R. Advani,et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. , 2010, Blood.
[21] T. Terasawa,et al. Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes , 2009, Leukemia & lymphoma.
[22] A. Rahmouni,et al. Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy , 2009, Journal of Nuclear Medicine.
[23] S. Goodman,et al. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[24] Michel Meignan,et al. Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.
[25] Emmanuel Itti,et al. Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis , 2007, Journal of Nuclear Medicine.
[26] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. O'Doherty,et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] Emmanuel Itti,et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. , 2005, Blood.
[29] A. Stamatoullas,et al. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] P. Dupont,et al. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] J. Leonard,et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] S. Hain,et al. 18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT , 2000, Leukemia & lymphoma.
[33] I. Lossos,et al. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] J. D. van der Walt,et al. The prognostic value of interim positron emission tomography scans combined with immunohistochemical data in diffuse large B-cell lymphoma. , 2005, Haematologica.
[35] G. Jerusalem,et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. , 2000, Haematologica.
[36] Wi Wei,et al. Prognostic factors , 1998, British Journal of Cancer.